MSK Therapeutics Accelerator

MSK Therapeutics Accelerator

MSK Therapeutics Accelerator

The goal of the MSK Therapeutics Accelerator is to develop and advance therapeutics for people with cancer.

types of collaborations
Learn about the MSK Therapeutics Accelerator, a business accelerator program launched by MSK in 2023. This selective partnership program fosters and accelerates innovative collaborations between MSK and biotech and pharmaceutical companies worldwide.

For more information or to apply, contact Eileen Flowers at [email protected].

As one of the world’s most respected comprehensive centers devoted exclusively to cancer, MSK has devoted more than 135 years to exceptional patient care, influential educational programs, and innovative research to discover more effective strategies to prevent, control, and ultimately, cure cancer.  The institution is home to an exceptional community of researchers, clinicians, and digital health professionals and it is committed to advancing the care and treatment of cancer around the globe through life sciences and digital health innovation.

At MSK, we are united by a relentless dedication to conquering cancer.  We are one of 56 National Cancer Institute-designated Comprehensive Cancer Centers, with state-of-the-art science and technology supporting clinical studies, personalized treatment, and compassionate care for our patients.  Last year, we treated over 210,000 patients.

In 2023, MSK’s Sloan Kettering Institute celebrated its 75th anniversary, with a record of discovery that includes important contributions to the fundamental understanding of human biology, as well as practice-changing innovations in the treatment of cancer.

Why work with us?

Among academic-research institutions, MSK is a leader in creating and developing innovation with impact. To date, the FDA has approved 13 therapeutics involving MSK inventions—and our institution has meaningfully contributed to the clinical development of many more.

For our industry partners, this accelerator program provides streamlined access to MSK facilities and infrastructure, as well as the opportunity to collaborate with our leading clinical and scientific experts through all stages of drug development through regulatory approval.

Other important benefits for MSK Therapeutics Accelerator participants include committed liaison support and enhanced predictability of contract timelines. As part of this program, each participating company will have a dedicated liaison, who will serve as the primary point of contact—managing the existing project while providing concierge support to streamline and accelerate the process.  This will facilitate additional engagement and work with other groups at MSK if/when such services are requested.

MSK Expertise and Resources

Learn more about how the MSK Therapeutics Accelerator program helps pharmaceutical and biotech companies accelerate drug development

Through all stages of developing new cancer therapeutics, MSK aims to jump-start the innovation process, by providing select projects with access to our expert teams and extensive preclinical research, product co-development, and clinical trial resources.  We do not provide financial resources through this program.

MSK Therapeutics Accelerator connects MSK’s industry partners with valuable institutional resources including potential access to our 33 state-of-the art core facilities which provide services and technology to support research. Our cores provide the highest quality of scientific technology and research support services in rapid turnaround time, while operating in a cost-effective manner. Each of the MSK core facilities is operated by research experts in the technologies and services offered.

Depending upon the nature of the project, MSK Therapeutics Accelerator program participants may utilize Core services such as:

  • MSK Organic Synthesis Core Facility: Can perform medicinal chemistry and compound optimization to generate Phase 1 enabling small molecule compounds. Expertise available but not limited to developing complex carbohydrates, precursors to radioisotope labeled PET agents, cold labeling strategies, nanomaterials, antibody conjugation, and structure-activity relationship (SAR) analysis.
  • MSK Antitumor Assessment Core: This Core routinely performs PK/PD studies and Good Laboratory Practice (GLP) toxicology studies. It also evaluates therapeutics in in vivo disease models in support of IND applications.  MSK’s centralized patient-derived xenograft (PDX) library offers access to a curated selection of PDX models developed from hospital samples; these are accompanied with clinical, histology, and genomic annotation to inform clinical development.
  • MSK Cell Therapy and Cell Engineering Core:  As one of the first cancer centers worldwide to treat patients with cell therapies, this Core routinely performs genetic engineering/transduction of patient cells, produces clinical grade vector, performs molecular analysis of gene transfer efficiency/transgene expression in patient cells, and conducts quality control of clinical reagents and patient cells. MSK has a proven ability to operationalize new cell therapies quickly and efficiently.
  • MSK Clinical Grade Production Core: Specializes in the manufacturing of therapeutics for early-stage clinical trials. This Core supports IND applications for small molecules, monoclonal antibodies, biologics, vitamins, and other therapeutics. Routinely performs monoclonal antibody purification, chelation of therapeutic antibodies for radiochemical labeling, and vialing/lyophilization of therapeutics. It also assists with enhancing the solubility of active pharmaceutical ingredients.
  • MSK Research Pharmacy Core: Assists in the manufacturing, packaging, distribution, and monitoring of clinical-stage therapeutics—most significantly, at advantageous price points. This Core includes MSK’s Pharmaceutical Product Facility, which performs formulations, stability assessment, and packaging of drug products, as well as the MSK Investigational Drug Service, which conducts drug distribution, monitoring, and protocol coordination.
  • MSK Product Development unit: Expert team able to plan, guide, and support IND application filings and IND-enabling studies. The unit, which includes dedicated staff with significant expertise communicating with the FDA on novel therapeutics, can provide guidance on IND applications (ex: design of PK, safety, pharmacology, and toxicology studies) as well as CMC sections (ex: formulation development, process development/GMP manufacturing) for first-in-human trials.
  • MSK Clinical Trials: MSK is a leader in cancer-related clinical trials, with 1,580+ interventional research studies ongoing, as of December 2023. To date, MSK has conducted more than 25 clinical trials involving MSK developed cell therapies.  With an outstanding record in clinical trial operations and administration, institutional resources include extensive teams with expertise in oncology patient care, clinical research operations and compliance, and clinical trials nursing, finance, and contracting.
  • Access to Consented, De-Identified Clinical Data and Samples from extensive and invaluable sources that include longitudinal clinical outcomes and genomic data, including microbiome data, and the MSK Biobank.
How to Collaborate

Inquiry and Selection Process

Wondering if the MSK Therapeutics Accelerator Program would be a good fit for your company’s therapeutics development focus? Reach out to Eileen Flowers, PhD, Director, Technology Development & Licensing, to discuss potential areas for collaboration with MSK’s expert professionals.

  1. Start. Get in touch with MSK Therapeutics Accelerator by contacting Eileen Flowers, [email protected] to start the conversation.  This program is open to applicants from biotech startups as well as larger and more mature biotech, pharmaceutical, and other healthcare companies.
  2. Evaluation & Matching.  This is an opportunity for MSK and potential program participants to discuss the scope of a planned project and potential opportunities for collaboration and project advancement with MSK faculty drug development and disease area experts.
  3. Negotiations & Contracting.  The nature and timing of these discussions will be project specific, but topics to be discussed will include research budget, IP and data rights, contractual obligations, and development/commercialization plans.
  4. Collaboration. While the terms of any collaboration will be highly project specific, it is anticipated that scoped activities will typically last between 1-3 years.
Contact Us

Eileen Flowers, PhD
Director, Technology Development & Licensing
Office of Technology Development
Contact: [email protected]